Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Advanced Solid Tumors

Description

N/A

Subjects with advanced or metastatic solid tumors (non-hematologic refractory to or relapsed from standard therapies or for which there is no known effective treatment during dose escalation
Subjects with squamous non-small cell lung cancer and triple-negative breast cancer or other solid tumor types for which Notch activation has been demonstrated (such as pancreatic, ovarian and melanoma) during dose expansion
Biopsy accessible tumor (may be waived under certain circumstances)
Life expectancy of at least 3 months
Eastern Cooperative Oncology Group (ECOG) 0-1
Adequate organ and bone marrow function

Infection
Elevated triglycerides
Gastrointestinal (GI) disease with increased risk of diarrhea [e.g. inflammatory bowel disease (IBD)]
Taking medications known to increase risk of Torsades De Pointes

Please contact Daisy Sosa to learn more about where you can participate in this trial. Please use the contact form on the right side.